# The FDA, Unicure, and the Limits of Accelerated Approval

Page: https://stenobird.com/podcast/the-doctor-s-lounge-7442524/the-fda-unicure-and-the-limits-of-accelerated-approval
Text version: https://stenobird.com/podcast/the-doctor-s-lounge-7442524/the-fda-unicure-and-the-limits-of-accelerated-approval.md
Podcast: [The Doctor's Lounge](https://stenobird.com/podcast/the-doctor-s-lounge-7442524)
Published: 2026-05-25T12:00:00+00:00
Episode link: https://api.riverside.com/hosting-analytics/media/0a0221050f5f11140efcac22b18ea955bf07d00346c2184c46a458d6e8b45317/eyJlcGlzb2RlSWQiOiI3OWQzMGI1MC1jZmE2LTQ1NWUtYWY2Yy00NGRhOGJmMWJlY2IiLCJwb2RjYXN0SWQiOiI1OTUwMWY1OS1hY2E0LTRkZWYtYmQ5OS1hMDQzYTY4MDIyNjMiLCJhY2NvdW50SWQiOiI2OTJmNTE0YTZlYjA1ZDMyNzdmZTA2OWQiLCJwYXRoIjoibWVkaWEvY2xpcHMvNjlmNGVhNzlhMzBmZDVmYTUxMDIxMjk3L2RvY3RvcnMtbG91bmdlcy1zdHVkaW8tY29tcG9zZXItMjAyNi01LTFfXzIwLTEtMjkubXAzIn0=.mp3
Audio file: https://api.riverside.com/hosting-analytics/media/0a0221050f5f11140efcac22b18ea955bf07d00346c2184c46a458d6e8b45317/eyJlcGlzb2RlSWQiOiI3OWQzMGI1MC1jZmE2LTQ1NWUtYWY2Yy00NGRhOGJmMWJlY2IiLCJwb2RjYXN0SWQiOiI1OTUwMWY1OS1hY2E0LTRkZWYtYmQ5OS1hMDQzYTY4MDIyNjMiLCJhY2NvdW50SWQiOiI2OTJmNTE0YTZlYjA1ZDMyNzdmZTA2OWQiLCJwYXRoIjoibWVkaWEvY2xpcHMvNjlmNGVhNzlhMzBmZDVmYTUxMDIxMjk3L2RvY3RvcnMtbG91bmdlcy1zdHVkaW8tY29tcG9zZXItMjAyNi01LTFfXzIwLTEtMjkubXAzIn0=.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-doctor-s-lounge-7442524/episodes/the-fda-unicure-and-the-limits-of-accelerated-approval
Duration seconds: 3189

## Resource

Episode Summary Anish sits down with Adu, a med student and biotech investor, to work through the FDA's contested handling of Unicure's AMT-130 — a gene therapy for Huntington's disease delivered via stereotactic brain injection. They debate whether the underlying data justifies approval, why the agency's mid-course reversal has rattled the investor community, and what the Sarepta precedent should have taught everyone involved. The conversation broadens into a bigger question: given that desperate patient populations will always demand access to anything showing a signal, who is actually best positioned to make the call on whether a drug works — the FDA, the clinician, or the market? Chapter Markers 00:00 FDA approval of AMT-130 and investor reaction 01:16 Unmet need and the case for regulatory flexibility 02:37 Sarepta, Duchenne's, and the cost of approving under pressure 05:09 Accelerated approval done right: the Amylyx example 09:14 Debating the AMT-130 data and the historical control problem 13:53 Why stock price matters for trial funding 17:20 How Prasad could have changed FDA culture differently 19:37 The FDA's role from Kefauver-Harris to today 22:26 Competing Huntington's therapies in the pipeline 25:39 Prasad's tenure: what worked, what didn't 28:27 Media coverage of the FDA and science journalism Co-Host Handles @anish_koka and @drdigiorgio Show Handle @drsloungepod

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-doctor-s-lounge-7442524/episodes/the-fda-unicure-and-the-limits-of-accelerated-approval/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-doctor-s-lounge-7442524/the-fda-unicure-and-the-limits-of-accelerated-approval.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.